2023
DOI: 10.1016/j.jval.2023.03.677
|View full text |Cite
|
Sign up to set email alerts
|

EE376 Estimated Financial Impact of the Drug Cladribine Incorporation for the Relapsing-Remitting Multiple Sclerosis Treatment (RRMS) in a Health Insurance Company in Brazil

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles